HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $7.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating for Akebia Therapeutics, maintaining a price target of $7.5.
September 06, 2024 | 11:27 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Akebia Therapeutics, with a maintained price target of $7.5, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $7.5 price target by a reputable analyst suggests a positive outlook for Akebia Therapeutics. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100